Some MCHR1 antagonists which were originally developed for use in obesity have since been considered for alternative clinical applications [e.g., Alb-127158(a) for irritable bowel disease]—though no such trials have yet commenced. Here, MCHR1 is linked to obesity due to melanocortin 4 receptor deficiency.